Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

EPS-3903 Is a Potent and Selective Oral STAT6 Inhibitor That Blocks Th2 Inflammation in an Ovalbumin Asthma Mouse Model

Friday, April 17, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses EPS-3903, a potent and selective oral inhibitor of STAT6, which has shown promise in blocking Th2 inflammation in a mouse model of asthma. This development could lead to new therapeutic options for asthma patients. The findings highlight the potential of EPS-3903 in addressing Th2-mediated inflammatory responses.
Price reaction · baseline $14.06 (2026-04-16 close) · hit pre-market · 4 other ENTA headline(s) in the window, move may be shared
day 0 close
-0.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • EPS-3903 shows potent and selective inhibition of STAT6.
  • Demonstrated effectiveness in blocking Th2 inflammation.
  • Potential for significant impact on asthma treatment.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is EPS-3903?

EPS-3903 is a potent and selective oral inhibitor of STAT6.

How does EPS-3903 affect asthma?

It blocks Th2 inflammation, which is significant in asthma pathology.

What model was used to test EPS-3903?

The efficacy of EPS-3903 was tested in an ovalbumin asthma mouse model.

What is the significance of STAT6 inhibition?

Inhibiting STAT6 can help reduce Th2-mediated inflammatory responses in asthma.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare EPS-3903 STAT6 asthma Th2 inflammation
Last updated: Apr 17, 2026

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →